Scientific director for the section on High-throughput Molecular Bioscience.
Professional Experience
-
1979: MSc in Engineering Chemistry, KTH, Stockholm, Sweden
-
1984: PhD in Biotechnology, Dept. of Biotechnology, KTH, Stockholm, Sweden
-
1985-86: Post doc, EMBL, Heidelberg, Germany (Dr Riccardo Cortese)
-
1987-1988: Associate Professor (Docent) in Biotechnology, KTH, Stockholm, Sweden
-
1988-: Professor in Microbiology, Dept. of Biotechnology, KTH, Stockholm, Sweden
-
1999-2001: Vice President external affairs, KTH, Stockholm, Sweden
Awards and Honors
Professor Uhlén has received numerous awards, including the Svedberg prize in 1992, the Göran Gustavsson prize in 1993, the gold medal of the Royal Swedish Academy of Engineering Sciences in 2004, the Most Noble Order of the Seraphim – the Order of His Majesty the King in 2004, the Jerker Porath award in 2005, the Akzo Noble Award in 2005, the HUPO Distinguished Award and KTH Great Prize both in 2006 and the Scheele prize in 2007.
Publication Summary
Professor Uhlén has more than 300 publications in bioscience with app. 15,000 citations and an h-index of 66. In the early 80s, Professor Uhlén cloned and characterized staphylococcal protein A which is now used extensively for purification of antibodies both in diagnostics and therapy. In the late 80s, Professor Uhlén published the use of magnetic micro spheres with streptavidin for automated solid phase applications. In the 90s, Professor Uhlén’s group described a new principle for affinity reagents, called Affibodies, and showed their use as research tools and recently as potential cancer therapeutics. Uhlén and colleagues also developed a new strategy for DNA analysis called Pyrosequencing, a method that has recently been further developed by a US company into a highly parallelized sequencing instrument.
Patenting and Technology Transfer
Professor Uhlén has more than 50 international patent applications. He has founded several companies, including Pyrosequencing AB (now Biotage AB), Affibody AB, SweTree Technologies AB, Magnetic Biosolutions AB (now Nordiag AS), Atlas Antibodies AB, and Creative Peptides AB.